Результаты поиска

Recent advances in anti-angiogenic therapy of cancer.

Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical trials all over the world. This review discusses agents that have approved by the FDA and are currently in use for treating patients either as single-agents or in combination with other chemotherapeutic agents.

Bisphosphonates and osteonecrosis of the jaw: a case report.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Early detection of acute cisplatin nephrotoxicity: interest of urinary monitoring of proximal tubular biomarkers.

BackgroundRenal toxicity induced by cisplatin (CisPt) is a clinical issue in patients with or without chronic kidney disease (CKD). Proximal tubular injury can result in acute kidney injury (AKI), which may compromise the course of chemotherapy and the prognosis. The purpose of this study was to investigate the time course of urinary markers of acute tubulotoxicity and to assess the usefulness of such monitoring in a routine clinical setting.MethodsThis work is an open prospective pilot study carried out among 23 patients receiving a platinum-based chemotherapy. Individual comorbidities, plasm

Совпадение в полном тексте источника
… Informed consent was obtained for each patient, and their respective oncologists were informed prior to the start of the study. … Conclusions Preventing CisPt-induced nephrotoxicity remains nowadays a real problem for the oncologist, and the ideal renoprotective agent is still to be discovered. …

Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform.

Digital health tools are increasingly being used in cancer care and may include electronic patient-reported outcome (ePRO) monitoring systems. We examined physicians' perceptions of usability and clinical utility of a digital health tool (GIMEMA-ALLIANCE platform) for ePRO monitoring in the real-life practice of patients with hematologic malignancies. This tool allows for the collection and assessment of ePROs with real-time graphical presentation of results to medical staff. Based on a predefined algorithm, automated alerts are sent to medical staff. Participating hematologists completed an o

Совпадение в полном тексте источника
… In the PRO-TECT trial ( 30 ), 91% of the oncologists who responded to the survey found ePRO information useful, and this finding is consistent with that observed in our survey, where 87% of hematologists declared to have better understood patients’ symptoms by using the platform. … Oncologist (2020) 25(4):e722–e32. doi: 10.1634/theoncologist.2019-0348 3. Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, et al. Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. …

Influence of Preventive Tooth Extractions on Quality of Life in Patients with Antiresorptive Intake-A Prospective Longitudinal Study.

BACKGROUND: To find out whether preventive tooth extractions in patients on antiresorptive therapy have a direct impact on the patients' overall quality of life (QoL); Methods: QoL using the five-level version of the EuroQol Group's EQ-5D instrument (EQ-5D-5L) was longitudinally assessed in N = 114 prospectively enrolled patients with indication of preventive tooth extraction over a period of 12 months. Patients were stratified as high-risk (malignant disease with bone metastasis or multiple myeloma, with monthly high-dose antiresorptive therapy delivered intravenously [bisphosphonate] or subc

Cost-effectiveness analysis of voice rehabilitation for patients with laryngeal cancer: a randomized controlled study.

IntroductionVoice problems are common following radiotherapy for laryngeal cancer. Few studies exist covering the effect of voice rehabilitation, and no previous studies exist regarding the cost of said rehabilitation. This randomized controlled study aimed to analyze the cost-effectiveness of voice rehabilitation after radiotherapy for patients with laryngeal cancer.Material and methodsA total of 66 patients with laryngeal cancer with follow-up data 12 months post-radiotherapy were included. Patients were randomized into receiving either voice rehabilitation (n = 32) or no voice rehabilitatio

Совпадение в полном тексте источника
… Table 2 Costs per patient during first year after radiotherapy presented in EUR (SD) | Total ( n = 66) | Voice rehabilitation ( n = 32) | No rehabilitation ( n = 34) | p value Number of visits to oncologists | 3.11 (0.98) | 3.09 (0.76) | 3.12 (1.15) | n.s. … Costs of visits to oncologists | 712 (224) | 709 (178) | 715 (263) | n.s. Number of hospital admission days to Oncology | 0.64 (2.58) | 0.59 (3.31) | 0.68 (1.59) | n.s. Costs of hospital admission to Oncology | 509 (2066) | 475 (2687) | 541 (1272) | n.s. …

Hematological malignancies in East Africa-Which cancers to expect and how to provide services.

BackgroundSub-Saharan Africa (SSA) has an increasing non-communicable disease burden. Tanzania has an incidence of more than 35,000 cancer cases per year with an 80% mortality rate. Hematological malignancies account for 10% of these cases. The numbers will double within the next 10 years due to demographic changes, better diagnostic capabilities and life style changes. Kilimanjaro Christian Medical Centre established a Cancer Care Centre (CCC) in December 2016 for a catchment area of 15 million people in Northern Tanzania. This article aims to display the hematological diagnosis and character

Analysis of Early Post-Radiation Surgical Management of Metastatic Spinal Tumors.

Background/Objectives: Radiotherapy is one of the various treatment options for patients with metastatic spinal tumors (MST). However, it is difficult to say that this is definitely an optimal treatment for MST, and there are several patients who need surgical treatment because pain or neurologic deficits occur even after radiotherapy. Therefore, this study aimed to analyze which patients received early operative treatment after radiotherapy. Methods: We included 81 patients who underwent decompression and fusion surgery after radiotherapy for MST. Patients who underwent surgery within 6 month

Совпадение в полном тексте источника
… The decision for treatment was based on a consensus in a multidisciplinary center consisting of medical oncologists, radiation oncologists and spine surgeons who took into consideration factors such as life expectancy, performance, symptoms and future systemic treatment plans. … The NOMS framework: Approach to the treatment of spinal metastatic tumors Oncologist 2013 18 744 751 10.1634/theoncologist.2012-0293 23709750 PMC4063402 31. Brande R.V.d Cornips E.M. Peeters M. Ost P. Billiet C. Van de Kelft E. …

Building a Sustainable Comprehensive Multiple Myeloma Program in Western Kenya.

Despite improved treatment strategies for multiple myeloma (MM), patient outcomes in low- and middle-income countries remain poor, unlike high-income countries. Scarcity of specialized human resources and diagnostic, treatment, and survivorship infrastructure are some of the barriers that patients with MM, clinicians, and policymakers have to overcome in the former setting. To improve outcomes of patients with MM in Western Kenya, the Academic Model Providing Access to Healthcare (AMPATH) MM Program was set up in 2012. In this article, the program's activities, challenges, and future plans are

Совпадение в полном тексте источника
… Adverse drug reaction monitoring was also done through phone call follow-ups and timely management offered in consultation with hemato-oncologists. These PV activities by the program enforced treatment adherence. … Oncologist 20:554-561, 2015 32. Olbara G, Martijn HA, Njuguna F, et al. : Influence of health insurance status on childhood cancer treatment outcomes in Kenya. Support Care Cancer 28:917-924, 2020 33. …

Exploring the rationale, experience and impact of using Cancer Information and Support (CIS) services: an international qualitative study.

PurposeThe aim of this study was to develop an in-depth understanding of the rationale, experiences, evaluation and outcomes of using Cancer Information and Support (CIS) services in Australia, the UK and USA.MethodsSemi-structured interviews were used to gather data between November 2015 and January 2016. Telephone interviews were recorded, de-identified, transcribed and thematically analysed. Ten users from each of three international CIS services (n = 30 in total) were recruited. Participants were eligible for inclusion if they had utilised the CIS in 2015 via telephone contact with a cance

Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access.

Autologous Chimeric antigen receptor (CAR) T-cell therapies have demonstrated substantial efficacy in patients with relapsed or refractory hematologic malignancies; however, their implementation has been constrained by regulatory barriers. Risk Evaluation and Mitigation Strategies (REMS), mandated by the U.S. Food and Drug Administration (FDA), were initially implemented to mitigate risks associated with cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and other treatment-related toxicities. On 27 June 2025, the FDA removed REMS requirements for

Совпадение в полном тексте источника
… Surveys suggest that community oncologists often hesitate to refer patients for CAR T-cell therapy due to uncertainty regarding eligibility, concerns about toxicity, logistical complexity, or unfamiliarity with the referral process. … Educate Community Providers Targeted education for community oncologists and referring providers is essential. Providers should be made aware of the REMS removal decision, the supporting safety evidence, and updated eligibility and monitoring protocols. …

A Glimpse into the Epidemiology of Geriatric Cancers in India: Report from the Indian Population Based Cancer Registries.

IntroductionIndian population is aging and the cancer rates are rising. Older adults (OAs)(≥60 years) with cancer require specialized care. However, data on geriatric cancer epidemiology is scarce.MethodsThe study compiled the geriatric cancer data from the published reports(2012-2014) of Indian population-based cancer registries(PBCRs).ResultsOf the 1,61,363 cancers registered in the Indian PBCRs, 72,446(44.9%) occur in OAs, with 21,805(30.1%), 18,349(25.3%), 14,645(20.2%), and 17,647(24.4%) occurring in 60-64, 65-69, 70-74, and ≥75year age groups. The truncated incidence rates for OAs are 55

Совпадение в полном тексте источника
… International and national organizations are trying to enhance knowledge and expertise among oncologists by conducting training programs and geriatric cancer workshops in conferences. … Survey for geriatric assessment in practicing oncologists in india. Cancer Res Stat Treat. 2019;2:232. 18. Pramesh CS, Badwe RA, Borthakur BB, Chandra M, Raj EH, Kannan T, et al. Delivery of affordable and equitable cancer care in india. …

Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).

Antibody-drug conjugates (ADCs) are anticancer drugs that combine cytotoxic small-molecule drugs (payloads) with monoclonal antibodies through a chemical linker and that transfer toxic payloads to tumor cells expressing target antigens. All ADCs are based on human IgG. In 2009, the Food and Drug Administration (FDA) approved gemtuzumab ozogamicin as the initial first-generation ADC. Since then, at least 100 ADC-related projects have been initiated, and 14 ADCs are currently being tested in clinical trials. The limited success of gemtuzumab ozogamicin has led to the development of optimization

Совпадение в полном тексте источника
… Two core characteristics are considered when oncologists select a qualified payload. … In addition to improving the ADC release mechanism, oncologists are also seeking to identify additional biomarkers. …

Spinal metastasis: narrative reviews of the current evidence and treatment modalities.

The treatment for spinal metastasis has evolved significantly during the past decade. An advancement in systemic therapy has led to a prolonged overall survival in cancer patients, thus increasing the incidence of spinal metastasis. In addition, with the improved treatment armamentarium, the prediction of patient survival using traditional prognostic models may have limitations and these require the incorporation of some novel parameters to improve their prognostic accuracy. The development of minimally-invasive spinal procedures and minimal access surgical techniques have facilitated a quicke

Living and dying with incurable cancer: a qualitative study on older patients' life values and healthcare professionals' responsivity.

BackgroundIn ageing Western societies, many older persons live with and die from cancer. Despite that present-day healthcare aims to be patient-centered, scientific literature has little knowledge to offer about how cancer and its treatment impact older persons' various outlooks on life and underlying life values. Therefore, the aims of this paper are to: 1) describe outlooks on life and life values of older people (≥ 70) living with incurable cancer; 2) elicit how healthcare professionals react and respond to these.MethodsSemi-structured qualitative interviews with 12 older persons with advan

Совпадение в полном тексте источника
… However, according to HCPs, patients tend to ask questions to their caregivers related to his/her specialism, e.g. asking an oncologist for cure. … With the knowledge they gain from this game, older adults are expected to be better equipped to discuss their situation with their oncologists) [ 30 ]. …

Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.

New cases of invasive cancer in the United States occur among nearly 1.5 million people annually. In 2007, more than 1,500 people died per day with this diagnosis. Cancer is responsible for nearly one in every four deaths reported in the country. Enormous amounts of money and research have been, and are being spent, in an attempt to improve these numbers. While prevention and early detection remain the key to long-term success, treatment in the neo-adjuvant, adjuvant and metastatic settings still centre around two main treatment modalities - radiation therapy and chemotherapy. This article wil

Совпадение в полном тексте источника
… The main barrier to the implementation of these advanced programmes is still the lack of clinical training and professional development of the clinical staff, i.e. radiation oncologist, physicist and/or dosimetrist. … The availability of radiation oncologists or cancer specialists further complicates the disparity of cancer care often encountered in these countries [ 42 ]. …

Symptom burden and quality of life in advanced head and neck cancer patients: AIIMS study of 100 patients

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Metastatic primary duodenal adeno-carcinoma responding to metronomic oral cyclophosphamide chemotherapy.

Primary adenocarcinoma of duodenum is a very rare tumour with a prevalence of only 0.3 to 1% of among all the tumours of gastrointestinal tracts. Localised tumours, if resected have good prognosis but those with metastates entails a poor prognosis, where generally palliation may be the only feasible option. Low dose continous cytotoxic treatment or metronomic chemotherapy prevents neoangiogenesis and chemoresistance thereby, provides excellent symptom relief and palliation in many advanced heavily pretreated solid malignancies. It offers as an affordable, less toxic therapy with moderate to go

Why and How Should Ethiopia Establish a Stem Cell Transplant Service? A Review Article.

Ethiopia is attempting to reduce cancer-related morbidity and mortality through a strategic national cancer control plan but according to Globocan 2020, hematologic malignancies particularly leukemia and non-Hodgkin's lymphoma rank among the top five leading causes of new cancer incidence and cause of death among all age groups in both sexes. Hematopoietic stem-cell transplantation (HSCT) is an advanced treatment modality that makes the only effective treatment for cancer and non-cancer-related hematologic diseases unresponsive to conventional therapy. Patients who need stem cell transplants m

Совпадение в полном тексте источника
… Presence of health workers (Hematologists, oncologists, pathologists, nurses, laboratory technologists, and pharmacists) to be trained and lead the program. Presence of media and a social platform to teach the public about conditions that can be cured with HSCT. Medical tourism. … Oncologist . 2015;20(4):386–392. doi: 10.1634/theoncologist.2014-0218 41. Broder MS, Quock TP, Chang E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits . 2017;10(7):366–373. 42. FMoH. …

Financial Toxicity in Patients With Breast Cancer Treated at Private Medicine Institutions in Brazil.

Financial toxicity (FT) refers to the negative impact of the financial burden of cancer diagnosis and treatment on patients' well-being. With rising global costs of oncologic therapies, diagnostics, and supportive care, FT has become a key concern in cancer care, influencing adherence, quality of life, and outcomes. Breast cancer, given its high prevalence and socioeconomic implications, is notably associated with FT. Beyond direct medical expenses, patients often face income loss and out-of-pocket costs for supportive care, which can significantly affect their therapeutic trajectory. Addressi

Совпадение в полном тексте источника
… M., Schrag D., et al., “The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out‐of‐Pocket Expenses and the Insured Cancer Patient's Experience,” Oncologist 18, no. 4 (2013): 381–390. 2. Zafar S. Y. and Abernethy A. … A., et al., “The Utility of Cost Discussions Between Patients With Cancer and Oncologists,” American Journal of Managed Care 21, no. 9 (2015): 607–615. 25. Huntington S. F., Weiss B. M., Vogl D. …